Immucor surges on FDA nod for blood transfusion technology
This article was originally published in Clinica
Executive Summary
Immucor, a provider of automated instrument-reagent systems for blood transfusion, saw its share price surge over 21% earlier this week, after gaining US approval for its second generation Galileo system, a high throughput instrument that can process up to 224 different samples simultaneously.